
The dangerously blurry line between wellness and medical tech
Let me catch you up. On July 15th, the Food and Drug Administration (FDA) sent Whoop a letter. In it, the FDA declared that Whoop — maker of a niche fitness tracker favored by elite athletes — had crossed a line. Its new Blood Pressure Insights feature, the regulator said, was being marketed to customers without undergoing the proper clearance process.
In response, Whoop pulled out the W word: wellness.
In the world of health and wearable tech, 'wellness' is sort of like a 'get out of jail free' card. Some advanced health features, like EKGs and atrial fibrillation notifications, require regulatory clearance before consumers can use them. These features could be interpreted as diagnostic in nature or prompt a person to make a medical decision. Others, like step tracking and blood oxygen measurements, don't require FDA oversight at all. They're simply meant to make living a healthy life easier by helping you visualize certain measurable markers. Those features fall under the wellness umbrella. They're 'just for fun.'
Whoop's Blood Pressure Insights feature, however, lies in murkier territory.
The way Whoop's feature works is that a user takes readings with a regular blood pressure cuff for calibration. Once that process is complete, Whoop says its tracker uses metrics like 'heart rate, heart rate variability, and blood flow patterns during sleep' to give an estimate of a person's systolic and diastolic blood pressure each morning. The FDA contends that 'providing blood pressure estimation is not a low-risk function' and that a blood pressure estimate inherently implies you're diagnosing hypo- or hypertension. In a statement, Whoop says it 'respectfully disagree[s]' and that this particular feature is more akin to tracking your sleeping respiratory rate. Under the wellness umbrella, Whoop argues it's able to bring an innovative feature to the masses more quickly.
Whoop and the FDA both have points. It's not a stretch to think that a user may get a few 'high' blood pressure estimates, assume they have high blood pressure, and make health decisions informed by that assumption. At the same time, it's clearly labeled as a beta feature, and similar 'diagnostic adjacent' features are available without FDA regulation. I've lost count of how many sleep trackers claim to track 'breathing disturbances.' That may not be explicitly marketed as a sleep apnea detection metric (that would require FDA clearance), but that's semantics. The obvious reason to include it is to flag when a person might want to check themselves for sleep apnea.
The crux of it all is identifying high- and low-risk features for causing harm. Many cases are clear-cut. Natural Cycles, for example, is a period tracking app that claims you can use it as digital contraception using temperature data from wearables like the Oura Ring. It's obvious that a regulatory body should vet a high-stakes feature like that. On the flip side, Samsung's new Antioxidant Index feature for its Galaxy Watch 8 is a silly metric that tells you whether you've eaten enough fruits and veggies. Even if it's inaccurate as hell (I was able to fool it by scanning a Cheez-It), it's not likely to harm your health.
Where the FDA's current process falls short is the increasing number of features that lie somewhere in the middle. Take the Oura Ring. A friend just asked me whether they should get one based on a TikTok video. In said video, celebrity DJ Dillon Francis says the main reason he has an Oura Ring is because it predicts when he's getting sick. This is the Symptom Radar feature, which, in simple terms, flags when you might be getting sick — and it's based on real clinical research conducted during the COVID-19 pandemic. It sounds diagnostic, which requires FDA clearance. But it's not. It's considered a wellness feature because it doesn't tell you what you're falling ill with — just that you might be showing 'early signs of a health change.' And while there's a distinct difference between a diagnosis and a heads-up, it can feel awfully similar to a layperson.
Also, Whoop isn't the only company exploring blood pressure tech. Samsung has a similar feature that's unavailable in the US, as it hasn't been cleared by the FDA. According to Bloomberg, Apple has also been working on an Apple Watch feature that flags when your blood pressure spikes above your baseline, but it reportedly won't spit out direct readings like a continuous glucose monitor would — possibly to avoid FDA clearance as a 'wellness' feature.
Perhaps that means it's time we acknowledge that wellness isn't an innocuous word anymore.
Beyond blood pressure, Samsung and Apple are also widely rumored to be working on blood glucose monitoring features, where the stakes for diabetics could be sky-high. If or when those features do become available, it's possible that companies will adjust how they work to more broadly fit under a wellness label. For instance, instead of glucose readings, you get a trend line or score. I'm skeptical of the average person being able to discern the nuance when even seasoned tech journalists sometimes struggle with the correct verbiage.
Maybe it seems silly to sound the alarm over semantics. But as politicians advocate for greater wearable adoption, the stakes have never been higher. In a better, ideal world, companies would abolish phrases like 'clinically proven' or 'medical grade' from marketing. The FDA would figure out a clearer framework for the design of a wellness feature versus a medical one. But we don't live in an ideal world — and that means it's up to the consumer to know the difference. Frankly, that's not going so well. Perhaps that means it's time we acknowledge that wellness isn't an innocuous word anymore.
Posts from this author will be added to your daily email digest and your homepage feed.
See All by Victoria Song
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Analysis
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Features
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Fitness
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Gadgets
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Health
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Science
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Wearable

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
5 hours ago
- Newsweek
Freeze Dried Fruit Recall Sparks Warning to Customers Across the US
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Doehler Dry Ingredient Solutions, LLC is recalling the Member's Mark brand of freeze-dried fruit variety packs due to fears the product is contaminated with Listeria monocytogenes. Newsweek attempted to reach the company via phone on Friday for comment but could not leave a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential for damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. Listeria monocytogenes is a bacterium that poses significant health risks, particularly to pregnant women, newborns, older adults, and individuals with weakened immune systems, according to the FDA. What To Know In the alert, the FDA notes that the products were distributed from July 1, 2025, until July 25, 2025, at Sam's Club retail locations. The states and territories impacted by this recall are: Alabama Arizona California Colorado Connecticut Delaware Florida Georgia Hawaii Iowa Indiana Illinois Idaho Kansas Louisiana Maryland Maine Mississippi Minnesota Missouri Michigan Montana North Carolina North Dakota Nebraska New Hampshire New Jersey New Mexico Nevada New York Ohio Oklahoma Pennsylvania South Carolina South Dakota Tennessee Texas Utah Virginia Wisconsin West Virginia Wyoming Puerto Rico The Member's Mark Freeze Dried Fruit Variety Pack's being recalled are in 15 count boxes with a UPC number of 1 93968 50900 2, the FDA said. The agency added that no illnesses have been reported as of Thursday. The alert has a chart listing the recalled products with corresponding lot code numbers and use by dates for consumers to cross reference. The problem was discovered via "internal testing," the FDA says. A 15-count package of freeze dried fruit variety packs can be seen in connection to a recall on July 31, 2025. (Photo by the U.S. Food and Drug Administration) A 15-count package of freeze dried fruit variety packs can be seen in connection to a recall on July 31, 2025. (Photo by the U.S. Food and Drug Administration) What People Are Saying The FDA on its website in part about the incubation period for Listeria infection: "There can be a substantial delay between the time of ingestion of contaminated food and the onset of serious symptoms. The average time from exposure to illness is approximately 30 days, but symptoms can appear as long as 90 days after exposure. It is important for consumers to know that the infection can occur as much as 90 days later, so that they can seek appropriate treatment if they have symptoms of Listeria infection." What Happens Next? Consumers are advised to contact Doehler Dry Ingredient Solutions, LLC's Customer Service via phone at (770) 387-0451 on weekdays from 8 a.m. to 5 p.m. ET with any additional questions, the FDA says. Health authorities continue to emphasize the importance of proper food storage and handling, particularly for ready-to-eat items. The FDA advises consumers to refrigerate perishable foods at and under 40°F, discard recalled products and properly sanitize surfaces that may have contacted suspected contaminated items to prevent the risk of cross-contamination.
Yahoo
6 hours ago
- Yahoo
This popular energy drink may accidentally contain alcohol—what parents need to know
A packaging error involving two well-known beverage brands has triggered a safety recall—and raised new concerns for parents who keep Celsius energy drinks in their homes. According to a press release from High Noon, some of its vodka seltzer was accidentally packaged in cans labeled as Celsius Astro Vibe Sparkling Blue Razz energy drinks. The mislabeled cans contain alcohol but were distributed under non-alcoholic branding, with no external indication that they include vodka. The error occurred when a shared packaging supplier mistakenly sent empty Celsius cans to High Noon, which then filled them with vodka seltzer. The affected cans were shipped out between July 21–23, 2025, and sold in Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia, and Wisconsin. 'Consumption of the liquid in these cans will result in unintentional alcohol ingestion,' the press release stated. Related: 5 million backyard pools recalled after fatal child drownings—what parents need to know Why this matters to moms If you're pregnant, breastfeeding, or have teens or tweens in the house who may be grabbing a Celsius from the fridge, this recall matters. It's possible that a can meant to provide an energy boost might instead contain alcohol—with no visual clues besides the lid color and lot code. Although no injuries or illnesses have been reported so far, the FDA has been notified, and High Noon is urging anyone with the affected cans to avoid drinking them and dispose of them immediately. Unintentional alcohol consumption can have serious implications for developing babies, young children, and adolescents. According to the Centers for Disease Control and Prevention (CDC), 'There is no known safe amount of alcohol use during pregnancy or while trying to get pregnant.' How to check your cans Look carefully at both the lot number and the lid color of any Celsius Astro Vibe Sparkling Blue Razz cans in your home. Do not consume if your can has a silver lid and a lot code between: L CCB 02JL25 2:55 to L CCB 02JL25 3:11 Cans with a black lid or different lot codes are not part of the recall and are safe to consume. The affected cans may have come from High Noon Beach Variety Packs, but even individual Celsius cans could be impacted, so it's important to check all relevant products. If you find a can that matches the lot code and silver lid description, dispose of it and contact High Noon Consumer Relations for a refund at: consumerrelations@ Related: Popular nursery chair recalled for overheating hazard—here's what parents need to know What this says about food safety labeling Labeling errors like this are rare but not unheard of. According to the FDA, 'food mislabeling' is one of the most common reasons for product recalls in the U.S. A 2022 study on product recall trends found that undeclared ingredients or wrong product contents are leading causes for consumer safety alerts. For parents juggling busy routines and making quick grocery runs, it's a reminder that we deserve better transparency and safeguards—especially when the consequences could impact kids. What to do next If you've purchased a High Noon Beach Variety Pack or a Celsius Astro Vibe Sparkling Blue Razz can recently: Check the lot code and lid color immediately. Do not consume if the product matches the affected range. Email High Noon Consumer Relations at consumerrelations@ for instructions and refund details. You can also refer to the official High Noon press release for additional guidance: High Noon recall notice. Sources: High Noon announces recall of its vodka seltzer beach pack due to inclusion of CELSIUS® Astro Vibe energy drink cans. July 29, 2025. PR Newswire. About alcohol use in pregnancy. Accessed July 30, 2025. Centers for Disease Control and Prevention. FDA 101: Product recalls. May 11, 2023. U.S. Food and Drug Administration. Undeclared allergens are the leading cause of recalls in 2023. March 15, 2023. Trustwell Blog.
Yahoo
6 hours ago
- Yahoo
1 Top Cryptocurrency That Can Overtake Ethereum by 2028, According to Standard Chartered Analyst Geoff Kendrick
Key Points Ethereum is viewed by many as the main blockchain for smart contracts and decentralized applications. Ethereum is also a network being used to tap into the potential of cryptocurrencies in the traditional payments industry. The two largest stablecoin companies issue their tokens on Ethereum's network, but will it be enough to stave off the competition? 10 stocks we like better than XRP › Since the crypto sector sprang to life right around the depths of the Great Recession, Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) have always operated as the one and two seeds -- Batman and Robin if you will. Bitcoin is the original cryptocurrency viewed as the bellwether of the industry. In recent years, many have begun to view Bitcoin and its finite 21 million tokens as a form of digital gold that can hedge inflation and serve as safe asset amid geopolitical uncertainty and the U.S. government's mounting debt situation. Ethereum, on the other hand, is viewed as the network that is the epicenter of smart contracts and decentralized applications. While Bitcoin's dominance doesn't look to be going anywhere, with a $2.3 trillion market cap, Standard Chartered analyst Geoff Kendrick thinks Ethereum could be vulnerable, with one top cryptocurrency set to flip Ethereum by 2028. The crypto story of the year Ethereum and Bitcoin have had strong years, particularly Bitcoin, which seems to become more ingrained in the mainstream financial world every day. But neither can come close to the year that XRP (CRYPTO: XRP) is having, up roughly 400% during the past year (as of July 31). Donald Trump's presidential election win back in November triggered a series of positive events for XRP, notably a change in leadership at the Securities and Exchange Commission (SEC). Once the Trump administration took office, the SEC quickly began settling or dropping major lawsuits including one against Ripple, the company behind XRP, which had been an overhang on the token for several years. Now, Kendrick thinks the run for XRP may have only just begun and that it's even possible that XRP overtakes Ethereum by 2028. As of this writing, Ethereum had a $460 billion market cap, while XRP had a $186 billion market cap. Kendrick's argument is built on the belief that XRP and Ripple will gain wider institutional adoption and begin to take share of cross-border payments market. Earlier this year, Ripple paid $1.25 billion to acquire the prime broker Hidden Road. Hidden Road offers institutional traders a wide range of services including clearing, prime brokerage, and funding for foreign exchange (FX), digital assets, derivatives, swaps, and fixed income. Ripple sees this as a way to continue to bridge the gap between institutional investors, digital assets, and payments. Earlier this year, Ripple Chief Executive Officer Brad Garlinghouse called out SWIFT's high cross-border transaction error rates, ranging from 6% to 11%. SWIFT, or the Society for Worldwide Interbank Financial Telecommunication, is used by banks all over the world to send payment instructions to one another, largely for the purpose of cross-border payments. Garlinghouse said he thinks Ripple and XRP could free up as much as $10 trillion in transfers through its near instant-settlement capabilities. The XRP network currently is capable of processing 1,500 transactions per second. Additionally, Garlinghouse believes XRP has the potential to take 14% of SWIFT's volume by 2030. Kendrick has a $5.50 price target on XRP by the end of this year, then $8 by 2026, and $12.50 by 2028. A $12.50 price would propel XRP's market cap to about $740 billion. XRP recently traded at about $3.10. Can XRP overtake Ethereum? Given the volatility in cryptocurrencies, I would always recommend that investors take crypto price targets with a grain of salt. Nobody can say for certain what will happen. However, cryptocurrencies with strong technical networks and use cases probably are the ones that will experience the most price appreciation. I find XRP and Ripple to be an intriguing story, and cross-border payments definitely seems to be a key area ripe for disruption by cryptocurrencies. While Ethereum is quite different from XRP, many stablecoins including the two largest U.S.-dollar backed stablecoins are issued on Ethereum's network, so it stands to benefit as well from increasing stabelcoin use. Although it's hard to say one way or another, I find it unlikely that XRP will overtake Ethereum in just a few years, primarily because Ethereum should benefit from cryptocurrencies and stablecoins taking payments volume. Ultimately, I find both Ethereum and XRP to be interesting cryptocurrencies with strong networks, so I do think investors can buy both. However, XRP has been more volatile, so I've been advising a smaller, more speculative position for now. Do the experts think XRP is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did XRP make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,049% vs. just 182% for the S&P — that is beating the market by 867.25%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Bram Berkowitz has positions in Bitcoin, Ethereum, and XRP. The Motley Fool has positions in and recommends Bitcoin, Ethereum, and XRP. The Motley Fool recommends Standard Chartered Plc. The Motley Fool has a disclosure policy. 1 Top Cryptocurrency That Can Overtake Ethereum by 2028, According to Standard Chartered Analyst Geoff Kendrick was originally published by The Motley Fool Sign in to access your portfolio